News
11hon MSN
Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.
10hon MSN
Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...
18h
MedPage Today on MSNMonotherapy for CLLThe initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.
An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...
1h
Stockhead on MSNDr Boreham’s Crucible: Sizing up the opportunity for ASX biotech AdheriumPlenty folk have an asthma puffer but few seem to know how to use it. Adherium says its Hailie device is improving compliance ...
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...
Building the future of health care: the need for investment in radiopharmaceutical commercialization
The efforts of CNIC and CMIE are setting the stage for this future, ensuring that Canada remains at the cutting edge of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results